Haleon PLC

Major Shareholding Notification • Jul 26, 2022

National Storage Mechanism | Additional information

RNS Number : 8258T

Haleon PLC

26 July 2022

26 July 2022

Haleon plc

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedi:			Haleon plc
1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Details of person subject to the notification obligation
Name			Glaxo Group Limited (and GlaxoSmithKline Finance plc and GlaxoSmithKline Holdings Limited as parent undertakings of Glaxo Group Limited)
City and country of registered office (if applicable)			London, England
4. Full name of shareholder(s) (if different from 3.)
Name			Vidacos Nominees Limited
City and country of registered office (if applicable)			London, England
5. Date on which the threshold was crossed or reached:			25 July 2022
6. Date on which issuer notified (DD/MM/YYYY):			25/07/2022
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B)
Resulting situation on the date on which threshold was crossed or reached	5.44	0		5.44	502,727,073
Position of previous notification (if applicable)	N/A	N/A		N/A

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights					% of voting rights
Direct (DTR5.1)		Indirect  (DTR5.2.1)			Direct (DTR5.1)		Indirect (DTR5.2.1)
GB00BMX86B70		502,727,073		N/A			5.44		N/A
SUBTOTAL 8. A		502,727,073					5.44
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument		Expiration date	Exercise/ Conversion Period			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights
			SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument	Expiration date		Exercise/ Conversion Period		Physical or cash Settlement			Number of voting rights	% of voting rights
					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)				X
Name	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
GSK plc	5.44		5.44
GlaxoSmithKline Holdings Limited	5.44		5.44
GlaxoSmithKline Finance plc	5.44		5.44
Glaxo Group Limited	5.44		5.44
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information
GSK plc is making this notification on behalf of Glaxo Group Limited, GlaxoSmithKline Finance plc and GlaxoSmithKline Holdings Limited. This notification relates to the acquisition by Glaxo Group Limited (a wholly owned subsidiary of GSK plc and the holder of other external minority interests of the GSK group) of GSK plc's direct retained 5.44% stake in Haleon plc. The GSK group's aggregate interest in Haleon plc remains unchanged following the transfer, as can be seen by referring to the TR-1 submitted by GSK plc on today's date in respect of its own notification obligation. Glaxo Group Limited holds its shares in Haleon plc via a custodian, Vidacos Nominees Limited (as detailed in section 4 above), which holds the legal title to those shares on Glaxo Group Limited's behalf pursuant to a custody arrangement. These calculations are based on an issued share capital of Haleon plc of 9,234,573,831 ordinary shares.

Place of completion	London, England
Date of completion	25 July 2022

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

HOLUNUNRUKUBUAR